Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  apoptosis inducer
Results 1-25 of 493 for your search:
Start Over
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TL32711-RAN-0094-PTL, NCI-2014-01549, 2014-001719-37, TL32711-0094, NCT02147873
Smac Mimetic TL32711 in Treating Older Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome, or Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: UPCC 15411, NCI-2011-03720, NCT01486784
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SOR-C13 01, NCI-2014-01152, NCT01578564
Chemotherapy and R-(-)-Gossypol Acetic Acid in Preserving the Larynx in Patients With Stage III or IV Laryngeal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HUM00043975, NCI-2012-01021, CR00040536, HUM 43975, UMCC 2010.101, NCT01633541
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: FEN T-14, NCI-2015-01195, NCT02495415
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0057, NCI-2015-01383, NCT02355535
Dexanabinol in Treating Patients With Recurrent Brain Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SK01-ETS2101, NCI-2012-01204, 111827, NCT01654497
Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: JW-231MM-102, NCI-2015-01078, NCT02426723
A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BO25323, NCI-2015-00926, 2014-001810-24, NCT02242942
Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: M14-358, NCI-2014-01763, 2014-000687-18, NCT02203773
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C16014, NCI-2013-01188, 163325, 2013-000326-54, U1111-1158-2646, NCT01850524
LCL161 in Treating Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0612, NCI-2014-01241, CLCL161AUS02T, NCT02098161
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC1125, NCI-2012-00518, 11-001987, NCT01737502
Digoxin in Treating Patients with Stage I-III Breast Cancer Planning to Undergo Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: J1232, NCI-2013-00513, A-17427, CIR00011086, NA_00072292, NA_00072292 / CIR00011086, SKCCC J1232, NCT01763931
Bcl-2 inhibitor GDC-0199 in Combination with Obinutuzumab and Ibrutinib in Treating Patients with Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14266, NCI-2015-00252, ML29533, NCT02427451
SMAC Mimetic LCL161 Alone or with Cyclophosphamide in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1381, NCI-2013-01276, CLCL161AUS01T, NCT01955434
Sodium Selenite and Radiation Therapy in Treating Patients with Metastatic Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PROS0047, NCI-2014-01361, 30587, 4593, IRB-30587, NCT02184533
Lenalidomide and AT-101 in Treating Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC128A, NCI-2009-01569, NCT01021345, NCT01003769
Trametinib and Digoxin in Treating Patients with Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: SCCC-01614, NCI-2014-01177, 012014-007, 8843, Mod4_STU 012014-007, NCT02138292
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
Start Over